key: cord-0078829-rvb40xas
authors: Engelhart, Emily; Lopez, Randolph; Emerson, Ryan; Lin, Charles; Shikany, Colleen; Guion, Daniel; Kelley, Mary; Younger, David
title: Massively Multiplexed Affinity Characterization of Therapeutic Antibodies Against SARS-CoV-2 Variants
date: 2022-05-12
journal: Antib Ther
DOI: 10.1093/abt/tbac011
sha: 7b0644a4671ee7ccdbf3524a72efc8de4347f0a6
doc_id: 78829
cord_uid: rvb40xas

Antibody therapies represent a valuable tool to reduce COVID-19 deaths and hospitalizations. Multiple antibody candidates have been granted emergency use authorization by the FDA and many more are in clinical trials. Most antibody therapies for COVID-19 are engineered to bind to the receptor-binding domain (RBD) of the SARS-CoV-2 Spike protein and disrupt its interaction with ACE2. Notably, several SARS-CoV-2 strains have accrued mutations throughout the RBD that improve ACE2 binding affinity, enhance viral transmission, and escape some existing antibody therapies. Here, we measure the binding affinity of 33 therapeutic antibodies against a large panel of SARS-CoV-2 variants and related strains of clinical significance using AlphaSeq, a high-throughput yeast mating based assay to determine epitopic residues, determine which mutations result in loss of binding, and predict how future RBD variants may impact antibody efficacy. We find that some antibodies are more susceptible to mutations in the RBD than others, for example Imdevimab and Sotrovimab display no loss in binding to B.1.1.7, B.1.351 and P.1 variants whereas we observe a 10-fold loss in binding of Etesevimab and Regdanvimab to these variants.

Antibody therapies represent a valuable tool to reduce COVID-19 deaths and alleviate the burden on healthcare systems. During the vaccine rollout, antibody therapies to treat COVID- 19 have served as a stopgap to save lives. With vaccines widely available, antibody therapies continue to play an essential role in treating patients who are unvaccinated, such as the immunocompromised, and those infected with viral variants that escape vaccine protection. Antibody therapies can be developed quickly, making them well suited for rapid response to newly emerging strain variants, and have proven to reduce both viral loads and hospitalizations (1, 2). Multiple antibody candidates have been granted emergency use authorization by the FDA and many more are in phase 2 and phase 3 clinical trials (3) (4) (5) .

Most antibody therapies for COVID-19 are engineered to bind to the receptor-binding domain (RBD) of the SARS-CoV-2 Spike protein and disrupt its interaction with angiotensin-converting enzyme 2 (ACE2) (6) (7) (8) (9) (10) . Since the first human transmission of COVID-19 over two years ago, SARS-CoV-2 has undergone significant antigenic drift arising from mutations throughout the RBD that improve ACE2 binding affinity, enhance viral transmission, and generate resistance to existing antibody therapies (11) (12) (13) (14) (15) (16) . Understanding the impact of observed and likely RBD variants on the effectiveness of antibody therapies is of critical importance.

A handful of antibody therapies have been granted emergency use authorization by the FDA, over a dozen are in late-stage clinical development, and many more are in preclinical development (17) . However, previous efforts to measure the effect of RBD variants on the efficacy of antibody candidates for COVID-19 have mostly been limited to characterizing individual SARS-CoV-2 RBD variants on a small number of antibody candidates (8, (18) (19) (20) (21) (22) (23) . A notable exception is the method introduced by Starr et al. which involves the construction of a yeast surface display library of RBD variants and enables the complete mapping of binding between a single antibody and all single mutations of the RBD (14, 15, 24, 25) . The low antibody throughput of this method, however, precludes characterization of a wide variety of clinically relevant antibodies.

The AlphaSeq assay, previously described as yeast synthetic agglutination, is presented here as a method for overcoming existing throughput challenges for characterizing the binding profiles of tens of antibodies against thousands of RBD variants (26) . Here, we leveraged the AlphaSeq assay to measure approximately 176,760 protein-protein interactions (PPIs) between 33 therapeutically relevant antibody candidates and most single-amino-acid mutations to SARS-CoV-2 RBD, along with selected widely circulating RBD variants containing multiple mutations. The PPI measurements are analyzed to derive key epitope residues for each antibody, determine individual or multiple mutations that result in loss of binding for each antibody, and predict how future RBD variants may impact antibody efficacy. Figure 1 presents the AlphaSeq assay and its application to antibody/RBD binding in schematic form.

First, to determine the epitope for each antibody, an AlphaSeq experiment was performed where 33 antibodies were screened against a site-saturation mutagenesis (SSM) library comprised of (after library preparation and sequencing) approximately 75% of all single-residue mutants of 165 sites within the SARS-CoV-2 RBD ( Fig. 2A, S1 , S2). While many RBD sites were intolerant to mutations (i.e., observed binding was poor across all antibodies and all mutants at that site), other sites revealed differential patterns of mutation-sensitivity among antibodies indicating epitopic diversity among the tested antibodies (Fig. 2B) . We carried out a pairwise comparison of binding among antibodies to distinguish epitope residues from intolerant sites where substitutions resulted in poor functional expression of the RBD (Fig. 2C) . For each site in the RBD included in the SSM library, all mutant affinities (scaled to each antibody's affinity to WT RBD) were compared between each pair of antibodies with a Mann-Whitney U test. A putative epitope residue was called if binding was found to be significantly impacted by substitutions relative to at least 4 other antibodies in the dataset (Bonferroni-corrected p-values ≤ .05). Sites without a putative epitope residue call are either non-epitope residues or to lie beyond the limit of detection of the assay. Overall, we found putative epitope residues for 22 antibodies (Fig. 2D, Table S7 , S8). For antibodies with known RBD-Ab structures and with multiple putative epitope residues, we found that our results correctly place key epitopic residues at the interface between the antibody and RBD (Fig. 2E) . However, for antibody CR3022, our method only found a single putative epitope residue (residue 455) and this residue is not present at the interface between the antibody and RBD (PDB ID 6ZLR). Overall, our results agree with previously published epitope data for COR-101, Imdevimab, Casirivimab, Bamlavimab, CC12.1 (19, 27, 28) while providing new insight into the epitopes targeted by the remaining antibodies and therefore allowing us to prospectively identify which RBD sites should be of particular concern for antibody binding in new strains of COVID-19.

Next, a second AlphaSeq experiment was performed to assess binding of the same 33 clinically relevant antibodies against a curated panel of coronavirus RBD variants. Included were 34 unique SARS-CoV-2 RBD variants with single, double, or triple mutations, including 5 CDCdefined variants of concern, B. (Fig. 3A) . From this single experiment, we quantitatively measured the binding of each antibody to each SARS-CoV-2 variant and characterized the cross-reactivity profile of each antibody to related coronavirus strains (Fig. S3 , Table S9 ).

The dataset includes 9 antibodies in clinical trials with publicly available sequences (29) . We observed a wide range of binding to the panel of SARS-CoV-2 RBD variants (Fig. 3B) . Notably, we found good concordance with previous literature reports for most antibody-variant interactions (Table S1 ). Of the 9 clinical antibodies, 3 antibodies have been extensively studied in the literature: Imdevimab, Casirivimab and Bamlanivimab (14, 18, 22, 23, 25, 30, 31) . We recapitulated the binding profiles for the B. As part of the same experiment, cross-reactivity was evaluated by measuring antibody binding to four additional RBDs from related coronaviruses: SARS-CoV-1, LYRa11, WIV1, and RaTG13. Some antibodies were found to be highly specific to SARS-CoV-2, including Imdevimab, Bamlanivimab, Regdanvimab, Tixagevimab, Cilgavimab, and COR-101. In contrast, Casirivimab, Sotrovimab, and Etesevimab demonstrate varying degrees of cross-reactivity.

From two AlphaSeq assays, we mapped binding of 33 anti-CoV antibodies against a panel of SARS-CoV-2 RBD variants, including B.1.1.7, B.1.351, and P.1, and identified key epitope residues for each antibody. Binding measurements for both AlphaSeq assays are included as supplementary files as well as the naming convention used for each antibody included in the dataset (Table S4, S5, S6) . This experiment has provided for the first time a comprehensive view of the impact of potential escape mutants (including several strains of substantial clinical concern) on the binding of RBD-targeted antibody therapeutics. For the small fraction of the dataset for which binding has been assayed previously, or for which the epitope is known via crystal structure, good agreement with previous methods establishes the reliability of AlphaSeq as a method. Specifically, 59 out 68 of the binding measurements in this work are in directional agreement with previous results that examined the effect of RBD mutations on the binding affinity of clinical antibodies (Table S1 ). However, we did not attempt to derive a correlation between our results and affinity values reported in the literature since reported values are dependent on the choice of antibody format, spike protein format and binding method, all of which vary among published datasets.

One of the limitations of this work is the expression of clinical antibodies as single-chain variable fragments (scFv) since we expect that this antibody format may not capture the viral neutralization capacity of an immunoglobulin G (IgG) or the native antibody conformation. A second limitation of this work is that our binding measurements were carried out with an RBD truncation (amino acids 319-527) expressed on the surface of yeast. Yeast primarily use highmannose N-glycosylation which can have implications for binding and structure. We also expect that differences in antibody and target expression, steric hindrance in binding due to the display orientation on the yeast surface, and the type of the assay used for comparison may explain some of the differences between AlphaSeq binding measurements and those reported in the literature. Finally, it is important to note that relative changes in antibody binding to yeast surface displayed RBD do not necessarily translate directly into changes of neutralization potency and require neutralization assays with fully assembled and human glycosylated virus for confirmation.

The results presented here begin to provide a deeper understanding of the impact of RBD mutations on the binding of therapeutic antibodies. Further validation of these results with additional orthogonal binding assays or viral neutralization assays is essential to prioritize the development of therapies effective against the widest possible variety of circulating and newly emerging viral variants, and to enable the eventual possibility of regional or even personal prioritization of the most effective therapies for circulating SARS-CoV-2 variants. Table #10 ). More detailed information for each antibody can be found in Supplementary Table #2 .

Coronavirus variants SARS-CoV-2 (isolate Wuhan-Hu-1, Genbank accession number MN908947, residues 319-527) and additional sarbecovirus homologs (RaTG13, Genbank MN996532; SARS-CoV-1 Urbani, Genbank AY278741; WIV1, Genbank KF367457; LYRa11, Genbank KF569996). CoV RBD sequences can be found in Supplementary Table #3 . 

Isogenic yeast plasmid transformation AlphaSeq compatible plasmids encoding yeast surface display cassettes were constructed by Twist Bioscience and resuspended at 100ng/µL. 100ng of plasmid was digested with PmeI enzyme for 1hr at 37°C to linearize, leaving chromosomal homology for integration into the ARS314 locus at both the 5' and 3' ends as described in (26 Nanopore barcode mapping Genomic DNA from yeast libraries was extracted using Yeast DNA Extraction Kit (Thermo Scientific) following the manufacturer's instructions. A single round of qPCR was performed to amplify a fragment pool from the genomic DNA containing the gene through the associated DNA barcode. qPCR was terminated before saturation to minimize PCR bias, generally between 15-20 cycles. The final amplified fragment was concentrated with KAPA beads, quantified with a Quantus (Promega), prepped with a SQK-LSK-110 ligation kit (Oxford Nanopore) and sequenced with a Minion R10 flow cell (Oxford Nanopore) following the manufacturer's instructions.

Library-on-Library AlphaSeq Assays 2 mL of saturated MATa and MATalpha library were combined in 800 mL of YPAD media and incubated at 30°C in a shaking incubator. 3 technical replicates were performed for each assay. After 16hr, 100 mL of yeast culture was washed once in 50 mL of sterile water and transferred to 600 mL of SDO-lys-leu with 100 nM ß-estradiol (Sigma) for 24hr. After 24hr, 100 mL of yeast was transferred to fresh SDO-lys-leu with 100 nM ß-estradiol for an additional 24hr. Library preparation for Next-Generation Sequencing Genomic DNA was extracted using Yeast DNA Extraction Kit (Thermo Scientific) following manufacturer's instructions. qPCR was performed to amplify a fragment pool from the genomic DNA and to add standard Illumina sequencing adaptors and assay specific index barcodes. qPCR was terminated before saturation to minimize PCR bias, generally between 23-27 cycles. The final amplified fragment was concentrated with KAPA beads, quantified with a Quantus (Promega), and sequenced with an NextSeq 500 sequencer (Illumina).

Both diploid barcode pairs counts, and haploid barcode counts were generated using Illumina sequencing as described above. Counts of diploid barcode pairs were normalized by dividing them by the product of of each corresponding haploid barcode counts to account for differences in library representation. A standard curve of proteins with known interacting partners and dissociation constant values was included in the assay and used to extrapolate dissociation constant values for the experimental protein interactions. Additional details on the computational approach to estimate dissociation constant values can be found in (26) . 

Figures S1 to S3 Tables S1 to S10 . RBD-CoV-2 intolerant substitutions results in loss binding for all antibodies in the set and appear as vertical dark blue streaks. C) Method summary for determination of epitope residues; each antibody was compared against all others, and at each RBD site a Mann-Whitney U test was performed to determine if binding was more impacted by a RBD mutations at that site in one antibody; results were filtered by U-test significance and for significance in 4 or more pairwise comparisons. D) Summary of epitope determination results. A putative epitope residue is represented as a navy color in the figure. An RBD residue is determined to be a putative epitope residue if binding was found to be significantly impacted by substitutions in that residue relative to at least 4 other antibodies in the dataset. This comparison is necessary to differentiate between substitutions that ablate binding to all antibodies, likely due to misfolding or low expression, versus substitutions that decrease binding to only a fraction of antibodies and therefore are more likely to be at the binding interface. The differential residue counts indicate the number of comparison antibodies for which a relative difference was found for a given antibody and RBD residue (summing the results from light-heavy and heavy-light orientations when both were tested). E) Representative antibodies (in blue) with known structure binding to RBD (in red), with residues called as epitope locations marked in white or yellow. in each column, values are mean difference in predicted binding affinity (measured on a log10 scale) between a given CoV variant and WT SARS-CoV-2 RBD for each antibody. Values below 0 (blue) represent improved binding relative to WT SARS-CoV-2 RBD and values above 0 (red) represent reduced binding affinity. In these data, Cilgavimab/AZD1061, Imdevimab/REGN10987 and Sotrovimab/GSK4182136 retain high affinity for the widest variety of clinically relevant RBD variants.

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial

Yancopoulos, I. Trial, REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19

COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19

Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic

Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies

Potential T-cell and B-cell Epitopes of 2019-nCoV. bioRxiv

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

V367F mutation in SARS-CoV-2 spike RBD emerging during the early transmission phase enhances viral infectivity through increased human ACE2 receptor binding affinity. bioRxiv

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity

Neutralizing monoclonal antibodies for treatment of COVID-19

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to known RBD mutations. bioRxiv

Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail. bioRxiv

Drug development of an affinity enhanced

Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

SARS-CoV-2 variants resist antibody neutralization and broaden host ACE2 usage. bioRxiv

Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape. bioRxiv

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. bioRxiv

High-throughput characterization of protein-protein interactions by reprogramming yeast mating

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Structural basis of a shared antibody response to SARS-CoV-2

COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19

SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination. bioRxiv

501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab in vitro. bioRxiv

CoV-AbDab: the Coronavirus Antibody Database